Skip to main content

Table 3 Propensity score analysis results 1: Survival impact across quintiles based on the propensity to receive chemotherapy among patients with metastatic non-small cell lung cancer, who survived at least 3 months after their cancer diagnosis (n = 7,879)

From: The effect on survival of continuing chemotherapy to near death

Analysis Variables HR (95%CI) P-value
Stratified analysis     
Lowest quintile of PS* No chemotherapy 1.00 - -
  Chemotherapy 0.82 (0.73, 0.93) < 0.01
Second quintile of PS No chemotherapy 1.00 - -
  Chemotherapy 0.77 (0.69, 0.85) < 0.001
Third quintile of PS No chemotherapy 1.00 - -
  Chemotherapy 0.81 (0.74, 0.90) < 0.001
Fourth quintile of PS No chemotherapy 1.00 - -
  Chemotherapy 0.85 (0.77, 0.93) < 0.01
Highest quintile of PS No chemotherapy 1.00 - -
  Chemotherapy 0.73 (0.66, 0.81) < 0.001
Multiple Cox regression adjustment using the PS No chemotherapy 1.00 - -
  Chemotherapy 0.76 (0.71, 0.82) < 0.001
  1. Abbreviation: HR, hazard ratio; CI, confidence interval; PS, propensity score.
  2. * Patients are least likely to receive "chemotherapy."
  3. † Patients are most likely to receive "chemotherapy."